Relay Therapeutics, Inc. (RLAY) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Median Dose Intensity | 99.00 percent | FY2026-Q2 |
| Overall Grade 3 Plus Treatment-Related Adverse Event Rate | 9.00 percent | FY2026-Q2 |
| Objective Response Rate | 44.00 percent | FY2026-Q1 |
| Patients With Grade 3 Hyperglycemia | 0.00 percent | FY2026-Q1 |
| Confirmed Objective Response Rate Across All Measurable Disease Patients | 39.00 percent | FY2024-Q4 |
| Clinical Benefit Rate | 67.00 percent | FY2024-Q4 |
| Median Progression-Free Survival | 11.40 ratio | FY2024-Q4 |
Back to RLAY overview · RLAY earnings · RLAY holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.